Patent SG-11201804648R-A (SG)
Title: Slc45a2 peptides for immunotherapy
Inventor: LIZEE GREGORY
IPC: C07K14/435
Filed: 2016-12-02
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau .... ..$) (43) International Publication Date r ,„„.. 8 June 2017 (08.06.2017) W I P0 1 PCT (10) WO International 111111111111311111111111111111111111111111111111111111111111111111111111111111111111111111 2017/096304 Publication Number Al (51) International Patent Classification: (81) Designated States (unless A61K 38/00 (2006.01) C07K 11/00 (2006.01) kind of national protection A61K 39/00 (2006.01) C07K 14/435 (2006.01) AO, AT, AU, AZ, BA, A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, DO, DZ, EC, EE, EG, (21) International Application Number: HN, HR, HU, ID, IL, PCT/US2016/064825 KW, KZ, LA, LC, LK, (22) International Filing Date: MG, MK, MN, MW, 2 December 2016 (02.12.2016) OM, PA, PE, PG, PH, SC, SD, SE, SG, SK, (25) Filing Language: English TN, TR, TT, TZ, UA, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless 62/263,189 4 December 2015 (04.12.2015) US kind of regional protection 62/263,835 7 December 2015 (07.12.2015) US GM, KE, LR, LS, MW, TZ, UG, ZM, ZW), Eurasian BB, CO, CR, CU, CZ, DE, DJ, DK, DM, ES, FI, GB, GD, GE, GH, GM, GT, IN, IR, LR, MX, MY, PL, PT, SL, SM, UG, MZ, otherwise available): otherwise available): indicated, for every AE, AG, AL, AM, BG, BH, BN, BR, BW, BY, IS, JP, KE, KG, KN, KP, KR, LS, LU, LY, MA, MD, ME, MZ, NA, NG, NI, NO, NZ, QA, RO, RS, RU, RW, SA, ST, SV, SY, TH, TJ, TM, US, UZ, VC, VN, ZA, ZM, indicated, for every ARIPO (BW, GH, NA, RW, SD, SL, ST, SZ, (AM, AZ, BY, KG, KZ, RU, (71) Applicant: BOARD OF REGENTS, THE UNIVER- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, SITY OF TEXAS SYSTEM [US/US]; 201 West 7th St., DK, EE, ES, FI, FR, Austin, TX 78701 (US). LV, MC, MK, MT, NL, (72) Inventors: LIZEE, Gregory; 9000 Almeda Road, Apt. SM, TR), OAPI (BF, GW, KM, ML, MR, NE, 3301, Houston, TX 77054 (US). YEE, Cassian; 8181 Fan- GB, GR, NO, BJ, CF, SN, CG, CI, CM, GA, GN, GQ, HR, HU, IE, IS, IT, LT, LU, PL, PT, RO, RS, SE, SI, SK, TD, TG). St. Apt. 1332, Houston, TX 77054 HWU, Published: nin (US). Patrick; 3317 Plum St., Houston, TX 77005 (US). — with international search report 21(3)) (Art ROSZIK, Janos; 2120 El Paseo St., Apt. 2407, Houston, TX 77054 (US). — with sequence listing part of description (Rule 5.2(a)) Agent: FINDLAY, Geoffrey, S.; Parker Highlander (74) PLLC, 1120 S. Capital of Texas Highway, Building One, Suite 200, Austin, TX 78746 (US). (54) Title: SLC45A2 PEPTIDES FOR IMMUNOTHERAPY FIG. IA Cutaneous melanoma Melanoma Metastatic melanoma 0V cc 00 00 (0 '01- (No CO CO CV 00 0) 0 C O C O L C ) CO LCD 0, C O L. \".. T- 0 0 C) CV 0.I Cr t- CO CC) Cv) 0J OJ r`.- LC' 0 0 \"-. '\". '''' --- - ''-i.• C O ( 9, C0 :''' CO CZ') C c .) ,-. CO Lei co co — m 0,1 0: 00 CS) CV CS) 1 1 1 '' ' 4 . .: 7 - ; - ' , I. 6 ::: ` C C C :: I N 4 4 cn.e, 4 4 cc:, 44444 &I 4 c(Qi SLC45A2 - — ®, . . Il MART -1 I . 4 t Gp100 1 1' 1yrosinase ° 0 GANN en . . 1 I ® , di c n hat ii C) Cr1 C:: , IN 1-1 (57) : Provided are SLC45A2 peptides that bind to MHC I (HLA-A2) on melanoma cells or other antigen-presenting cells are recognized by T-cell receptors on T cells. The SLC45 A2 peptides may be therapeutically used to treat a cancer, such as a N and cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T 0 cells that target SLC45A2 are also provided.